Philip Wagenheim
Known title: DirectorCIK: 0001405684
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Swarmer Signs MOU with Vectus for Up to 120 Mobile Air Defense Systems. Swarmer Inc. has entered a nonbinding memorandum of understanding with Vectus Air Defense Systems to deploy up to 120 mobile air defense units. The units are priced between $5 million and $6 million each, indicating a potential revenue opportunity. The agreement is a first step toward expanding Swarmer’s presence in the defense market. The deal is still subject to further negotiation and approval.
Transaction History
| IMNM | ▼ Sell | Open Market | 28,200 | $582K | 3/23/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 36,800 | $753K | 3/20/2026 | View on chart |
| SWMR | ▼ Sell | Other | 1,124,981 | — | 3/18/2026 | View on chart |
| IMNM | ▲ Buy | Grant | 8,750 | $35K | 1/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.